Skip to content

Clinical Research on the Treatment Model of Ambulatory Surgery for Colorectal Cancer

Open, Parallel, Randomized Controlled, Non-inferior, Phase III Clinical Research on the Treatment Model of Ambulatory Surgery for Colorectal Cancer

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06637215
Enrollment
352
Registered
2024-10-15
Start date
2023-11-01
Completion date
2029-03-31
Last updated
2024-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Carcinoma, Day Surgery

Keywords

Colorectal cancer, Day surgery, Laparoscope

Brief summary

To investigate the postoperative complication incidence and long-term efficacy between ambulatory surgery for colorectal cancer and traditional laparoscopic colorectal surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions。

Interventions

PROCEDURElaparoscopic colorectal day surgery

laparoscopic colorectal day surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions

PROCEDUREtraditional laparoscopic colorectal surgery

traditional laparoscopic colorectal surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions

Sponsors

First Hospital of China Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Patients voluntarily joined this study and signed an informed consent form; 2. Age: 18-75 years old; 3. The patient should have a good general condition and no serious internal medicine comorbidities (ASA classification of the American Anesthesiology Association is Grade I\ III); 4. Complete colonoscopy and colonoscopy biopsy, and the pathology is confirmed to be adenocarcinoma/high-level intraepithelial neoplasia; 5. Enhanced CT or MRI examination before surgery, indicating that the tumor diameter is ≤5.0 cm; 6. Preoperative staging: cT1-3NanyM0; 7. Strictly follow the colorectal day surgery plan, and micro-laparoscopic radical colorectal cancer treatment can be adopted; 8. There are no contraindications for abdominal wall nerve block anesthesia or non-opiate analgesic drugs; 9. Does not require conventional anticoagulant therapy or antiplatelet therapy; 10. Relatives or co-residents should be able to provide 24 hours of full escort within at least 72 hours after the operation, the place of residence is not more than a 30-minute drive from the hospital, and they can understand and follow the phased treatment plan of diet, analgesic drugs, etc. after the operation.

Exclusion criteria

1. Elderly patients with multiple basic diseases; 2. Moderate to severe anemia; 3. Severe hypoproteinemia; 4. Diabetes that is not well controlled; 5. Contraindications to laparoscopic surgery; 6. Cases of emergency surgery due to acute intestinal obstruction, perforation or bleeding; 7. Patients with distant metastases; 8. Patients who are unwilling to sign informed consent or follow-up according to the research plan; 9. People with a history of psychotropic drug abuse and unable to quit or have mental disorders; 10. Patients who live alone or in psychosocial isolation, patients who cannot understand the postoperative nursing process; 11. After the operation, the place of residence is far away from the treated hospital or patients with insufficient medical resources and inconvenient transportation; 12. According to the judgment of the researcher, there are concomitant diseases that seriously endanger the safety of the patient or affect the completion of the patient's research.

Design outcomes

Primary

MeasureTime frame
Recurrence-free survival (DFS)From enrollment to the end of treatment at 36 months
Overall survival (OS)From enrollment to the end of treatment at 36 months

Secondary

MeasureTime frameDescription
Cardiac disordersFrom enrollment to the end of treatment at 1 weekGrade 1: Mild; Grade 2: Moderate; Grade 3: Severe but not immediately life-threatening; Grade 4: Life-threatening; Grade 5: Death. Acute coronary syndrome Grade 1: - Grade 2: symptomatic, progressive angina; cardiac enzymes normaI; hemodynamicaIIy stabIe; Grade 3: symptomatic, unstabIe angina and/or acute myocardiaI infarction, cardiac enzymes abnormaI, hemodynamicaIIy stabIe; Grade 4: symptomatic, unstabIe angina and/or acute myocardiaI infarction, cardiac enzymes abnormaI, hemodynamicaIIy unstabIe. Grade 5: Death.
CoIonic fistuIaFrom enrollment to the end of treatment at 1 weekGrade 1: Mild; Grade 2: Moderate; Grade 3: Severe but not immediately life-threatening; Grade 4: Life-threatening; Grade 5: Death. Grade 1: Asymptomatic; cIinicaI or diagnostic observations onIy; intervention not indicated; Grade 2: symptomatic; aItered gastrointestinaI function; Grade 3: severeIy aItered GI function; boweI rest, TPN or hospitaIization indicated; eIective operative intervention indicated; Grade 4: Life-threatening; Grade 5: Death.
BIood system disordersFrom enrollment to the end of treatment at 1 weekGrade 1: Mild; Grade 2: Moderate; Grade 3: Severe but not immediately life-threatening; Grade 4: Life-threatening; Grade 5: Death. Anemia: Grade 1: HemogIobin (Hgb) \<LLN - 10.0 g/dL; \<LLN - 6.2 mmoI/L; \<LLN - 100 g/L; Grade 2: Hgb \<10.0 - 8.0 g/dL; \<6.2 - 4.9 mmoI/L; \<100 - 80g/L; Grade 3: Hgb \<8.0 - 6.5 g/dL; \<4.9 - 4.0 mmoI/L; \<80 - 65g/L; transfusion indicated; Grade 4: Life-threatening consequences; urgent intervention indicated; Grade 5: Death.
AnorectaI infectionFrom enrollment to the end of treatment at 1 weekGrade 1: Mild; Grade 2: Moderate; Grade 3: Severe but not immediately life-threatening; Grade 4: Life-threatening; Grade 5: Death. AnorectaI infection Grade 1: LocaIized; IocaI intervention indicated; Grade 2: OraI intervention indicated (e.g. , antibiotic, antifungaI, antiviraI); Grade 3: IV antibiotic, antifungaI, or antiviraI intervention indicated; radioIogic, endoscopic, or operative intervention indicated; Grade 4: Life-threatening consequences; urgent intervention indicated; Grade 5: Death.
FeverFrom enrollment to the end of treatment at 1 weekGrade 1: Mild; Grade 2: Moderate; Grade 3: Severe but not immediately life-threatening; Grade 4: Life-threatening; Grade 5: Death. Fever Grade 1: 38.0 - 39.0 degrees C (100.4 - 102.2 degrees F); Grade 2: \>39.0 - 40.0 degrees C (102.3 - 104.0 degrees F); Grade 3: \>40.0 degrees C (\>104.0 degrees F) for \<=24 hrs; Grade 4: \>40.0 degrees C (\>104.0 degrees F) for \>24 hrs; Grade 5: Death.
AbdominaI infectionFrom enrollment to the end of treatment at 1 weekGrade 1: Mild; Grade 2: Moderate; Grade 3: Severe but not immediately life-threatening; Grade 4: Life-threatening; Grade 5: Death. AbdominaI infection Grade 1: - Grade 2: - Grade 3: IV antibiotic, antifungaI, or antiviraI intervention indicated; radioIogic or operative intervention indicated; Grade 4: Life-threatening consequences; urgent intervention indicated; Grade 5: Death.
Pain evaluationFrom one hour after surgery to the end of treatment at 48 hoursVisual analogue scale (VAS) Using a ruler with 10 scales, and the two ends of the ruler are 0 and 10. 0 points indicate painless, and 10 points represent the most severe pain that is unbearable. The patients mark the corresponding position on the ruler that can represent the degree of pain. The doctor assigns a score to the patient based on the position marked by the patient. 2-4 points represent mild pain, 5-7 points represent moderate pain, and 8-9 points represent severe pain.

Countries

China

Contacts

Primary ContactKai Li
cmu_likai@163.com8613998245233

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026